The I-PWG has prepared and made available to the public an informational brochure on exploratory biomarker research intended for IRBs/IECs and Investigational Site Staff involved in clinical trials having an exploratory biomarker research component.
The brochure addresses issues relevant to specimen collection for biomarker research in the context of pharmaceutical drug and vaccine development.
New: Japanese version available! Click on the download button for all language versions currently available.
I-PWG has prepared and made available to the public an Informational Brochure intended for IRBs/IECs and Investigational Site Staff involved in clinical trials having a pharmacogenomic (DNA) component.
The brochure describes the added value of pharmacogenomic research in pharmaceutical drug development. Topics covered include, informed consent, return of genetic data to subjects, privacy/confidentiality, and sample coding methods.
I-PWG is a voluntary and informal association of pharmaceutical companies engaged in research in the science of pharmacogenomics. The Group’s discussions, activities and programs are open and transparent. They are limited exclusively to non-competitive matters. More about the group.
Actelion Pharmaceuticals Ltd., Amgen, Astellas, Biopharma, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Millenium, Novartis, Orion Pharma, Pfizer, Purdue Pharma, Regeneron, Roche/Genentech, Sanofi Aventis, Teva Pharmaceutical